Results 251 to 260 of about 126,534 (277)
Some of the next articles are maybe not open access.
Glucagon-like peptide-1 and glucagon-like peptide-2
Best Practice & Research Clinical Endocrinology & Metabolism, 2004The glucagon-like peptides (glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)) are released from enteroendocrine cells in response to nutrient ingestion. GLP-1 enhances glucose-stimulated insulin secretion and inhibits glucagon secretion, gastric emptying and feeding. GLP-1 also has proliferative, neogenic and antiapoptotic effects on
Laurie L. Baggio, Daniel J. Drucker
openaire +1 more source
Metabolic Messengers: glucagon-like peptide 1
Nature Metabolism, 2021Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents ...
Fiona M. Gribble, Frank Reimann
openaire +2 more sources
Glucagon-like peptide-1 agonists
BMJ, 2012Cannot be recommended strictly for weight reduction until their benefits and risks are ...
openaire +2 more sources
Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012Patients with type 2 diabetes mellitus are at high risk for developing cardiovascular diseases. Traditional medicines for type 2 diabetes, such as sulfonylureas, pioglitazone, and insulin have glucose lowering effects; however, they also increase the frequency of hypoglycemia and/or body weight and thus may cancel out the benefits of glucose lowering ...
Tomoya, Mita, Hirotaka, Watada
openaire +2 more sources
Glucagon-like peptide-1 receptor
Current BiologyMichael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
openaire +2 more sources
Glucagon-like Peptide-1 and Islet Lipolysis
Hormone and Metabolic Research, 2004A role for glucagon-like peptide 1 (GLP-1) has been suggested in stimulating beta-cell lipolysis via elevation of cAMP and activation of protein kinase A, which in turn may activate hormone-sensitive lipase (HSL), thereby contributing to fatty acid generation (FFA) from intracellular triglyceride stores.
M, Sörhede Winzell, B, Ahrén
openaire +2 more sources
Glucagon-Like Peptide 1—A Cardiologic Dimension
Trends in Cardiovascular Medicine, 2010Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant.
Treiman, Marek +3 more
openaire +3 more sources